Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Common Equity (2020 - 2025)

Xeris Biopharma Holdings (XERS) has disclosed Common Equity for 6 consecutive years, with $13.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Common Equity rose 146.22% year-over-year to $13.7 million, compared with a TTM value of $13.7 million through Dec 2025, up 146.22%, and an annual FY2025 reading of $13.7 million, up 146.22% over the prior year.
  • Common Equity was $13.7 million for Q4 2025 at Xeris Biopharma Holdings, up from -$861000.0 in the prior quarter.
  • Across five years, Common Equity topped out at $96.5 million in Q1 2022 and bottomed at -$35.1 million in Q1 2025.
  • Average Common Equity over 5 years is $17.0 million, with a median of $8.8 million recorded in 2023.
  • The sharpest move saw Common Equity skyrocketed 2336.49% in 2022, then tumbled 832.81% in 2024.
  • Year by year, Common Equity stood at $95.2 million in 2021, then tumbled by 52.55% to $45.2 million in 2022, then plummeted by 115.01% to -$6.8 million in 2023, then plummeted by 336.67% to -$29.6 million in 2024, then skyrocketed by 146.22% to $13.7 million in 2025.
  • Business Quant data shows Common Equity for XERS at $13.7 million in Q4 2025, -$861000.0 in Q3 2025, and -$19.3 million in Q2 2025.